NEO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

188.40M

+9.53%

0.024

-52.3%

187.98M

+11.87%

0.042

+4.17%

Estimates Revision

The market is revising Upward the revenue expectations for NeoGenomics, Inc. (NEO) for FY2025, with the revenue forecasts being adjusted by 0.43% over the past three months. During the same period, the stock price has changed by 49.19%.

Revenue Estimates for FY2025

Revise Upward

+0.43%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-1.06%

In Past 3 Month

Stock Price

Go Up

+49.19%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast NEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEO is 13.67 USD with a low forecast of 11.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

6 Hold

0 Sell

Moderate Buy

Current: 11.920

Low

11.00

Averages

13.67

High

17.00

Current: 11.920

Low

11.00

Averages

13.67

High

17.00

BofA

Neutral

maintain

$11 -> $13

2025-12-15

New

Reason

BofA

Price Target

$11 -> $13

2025-12-15

New

maintain

Neutral

Reason

BofA raised the firm's price target on NeoGenomics to $13 from $11 and keeps a Neutral rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and development.

Piper Sandler

Overweight

maintain

$11 -> $12

2025-11-10

Reason

Piper Sandler

Price Target

$11 -> $12

2025-11-10

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on NeoGenomics to $12 from $11 following quarterly results. The firm keeps an Overweight rating on the shares.

BofA

Neutral

maintain

$11

2025-10-29

Reason

BofA

Price Target

$11

2025-10-29

maintain

Neutral

Reason

BofA raised the firm's price target on NeoGenomics to $11 from $6.50 and keeps a Neutral rating on the shares after "a solid quarter." The firm views the quarterly update as "constructive," but sees questions on the sustainability of the growth rate and the competitive position, the analyst tells investors.

Leerink

Market Perform

maintain

$12 -> $14

2025-10-28

Reason

Leerink

Price Target

$12 -> $14

2025-10-28

maintain

Market Perform

Reason

Leerink raised the firm's price target on NeoGenomics to $14 from $12 and keeps a Market Perform rating on the shares. The company reported a Q3 beat and is taking investor feedback by proving "beatable guidance and realistic targets," the analyst tells investors in a research note.

TD Cowen

Buy

upgrade

$10 -> $12

2025-09-12

Reason

TD Cowen

Price Target

$10 -> $12

2025-09-12

upgrade

Buy

Reason

TD Cowen raised the firm's price target on NeoGenomics to $12 from $10 and keeps a Buy rating on the shares after hosting meetings with management. The firm left more constructive on NeoGenomics's new product launches, saying MolDX reimbursement remains the "final gate" for a 2026 ramp.

Stephens

Overweight

maintain

$11

2025-09-02

Reason

Stephens

Price Target

$11

2025-09-02

maintain

Overweight

Reason

Stephens raised the firm's price target on NeoGenomics (NEO) to $11 from $6.50 and keeps an Overweight rating on the shares after the company announced that a North Carolina district court ruled in the company's favor in the litigation with Natera (NTRA). The ruling grants NeoGenomics the ability to broadly commercialize RaDaR ST and removes an overhang, says the analyst, who believes the decision strengthens NeoGenomics' positioning in oncology and helps to support more durable growth.

Valuation Metrics

The current forward P/E ratio for Neogenomics Inc (NEO.O) is 79.45, compared to its 5-year average forward P/E of 0.08. For a more detailed relative valuation and DCF analysis to assess Neogenomics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

0.08

Current PE

79.45

Overvalued PE

126.36

Undervalued PE

-126.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

119.85

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1435.66

Undervalued EV/EBITDA

-1195.95

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.39

Current PS

0.00

Overvalued PS

7.80

Undervalued PS

0.98

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NEO News & Events

Events Timeline

No data

News

7.0

12-15Businesswire

NeoGenomics Wins Case as Natera Withdraws Appeal

5.0

12-15Newsfilter

NeoGenomics to Fully Launch RaDaR ST Assay in Q1 2026 Following Legal Victory

5.0

12-12PRnewswire

Netmarble Unveils New Trailer for The Seven Deadly Sins: Origin, Global Pre-Registration Now Open

People Also Watch

Frequently Asked Questions

What is Neogenomics Inc (NEO) stock price today?

The current price of NEO is 11.92 USD — it has increased 0.59 % in the last trading day.

What is Neogenomics Inc (NEO)'s business?

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.

What is the price predicton of NEO Stock?

What is Neogenomics Inc (NEO)'s revenue for the last quarter?

Neogenomics Inc revenue for the last quarter amounts to 187.80M USD, increased 11.90 % YoY.

What is Neogenomics Inc (NEO)'s earnings per share (EPS) for the last quarter?

Neogenomics Inc. EPS for the last quarter amounts to -0.21 USD, increased 50.00 % YoY.

What changes have occurred in the market's expectations for Neogenomics Inc (NEO)'s fundamentals?

How many employees does Neogenomics Inc (NEO). have?

Neogenomics Inc (NEO) has 2200 emplpoyees as of December 16 2025.

What is Neogenomics Inc (NEO) market cap?

Today NEO has the market capitalization of 1.54B USD.